FDA Approves FluMist Nasal Spray, First Self-Administered Flu Vaccine

Sep 20, 2024, 08:01 PM

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self- or caregiver-administration. This approval, announced on Friday, marks the first time a self-administered flu vaccine can be administered without the need for a healthcare provider. FluMist is licensed for individuals aged 2 to 49 and will be available for at-home use starting next flu season. Patients will need to complete a screening and eligibility assessment through a third-party pharmacy before obtaining the vaccine. The FDA's decision is part of its broader effort to expand consumer access to medicines and reduce healthcare costs and barriers, providing an alternative to flu shots.